

COPY OF PAPERS
ORIGINALLY FILED

1904D 0
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Peters, S. et al
Serial No. : 10/036,224
Filed : November 9, 2001
For : FAP-activated anti-tumour compounds

Docket No.: 1/1165
) Art Unit: To be assigned
) Examiner: To be assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

David A. Dow
Attorney for Applicant(s)
Reg. No. 46,124


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 798-9988
Docket No. 1/1165

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on February 28, 2002

By: David A. Dow
Reg. No. 46,124




COPY OF PAPERS
ORIGINALLY FILED

Substitute for form 1449A/PTO				Complete If Known	
PATENT DOCUMENTS SUBMITTED BY APPLICANT				Application Number	10/036,224
				Filing Date	November 9, 2001
				First Named Inventor	Peters, S. et al
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	1	Attorney Docket Number	1/1165

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AUS1	4,703,107		Monsigny, M. et al	10/27/1987	
	AUS2					
	AUS3					
	AUS4					
	AUS5					
	AUS6					
	AUS7					
	AUS8					
	AUS9					
	AUS10					
	AUS11					
	AUS12					
	AUS13					
	AUS14					
	AUS15					
	AUS16					

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AF1	WO	97/12624	/	Merck & Co.	04/10/1997		<input type="checkbox"/>
	AF2	WO	97/14416	/	Merck & Co.	04/23/1997		<input type="checkbox"/>
	AF3	WO	00/33888	/	Coulter Pharmaceuticals, Inc.	06/15/2000		<input type="checkbox"/>
	AF4	EP	0 624 377	/	Bristol-Myers Squibb	11/17/1994		<input type="checkbox"/>
	AF5	WO	97/45117	/	Prototek, Inc.	12/04/1997		<input type="checkbox"/>
	AF6	EP	0 255 341	/	Sunstar Kabushiki Kaisha	02/03/1988		<input type="checkbox"/>
	AF7	EP	0 126 685	/	Centre National de la Recherche Scientifique	11/28/1984		<input type="checkbox"/>
	AF8	WO	98/04277	/	Univ. of Pittsburgh	02/05/1998		<input type="checkbox"/>
	AF9	DE	196 40 970	/	Bayer AG	04/16/1998		<input type="checkbox"/>
	AF10	WO	00/64486	/	Veritas Medical Technologies, Inc.	11/02/2000		<input type="checkbox"/>
	AF11	WO	98/13059	/	Bristol Myers Squibb Co.	04/02/1998		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



COPY OF PAPERS
ORIGINALLY FILED

Substitute for form 1449B/PTO NON-PATENT DOCUMENTS SUBMITTED BY APPLICANT				Complete If Known	
				Application Number	10/036,224
				Filing Date	November 9, 2001
				First Named Inventor	Peter, S. et al
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	1	Attorney Docket Number	1/1165

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	AO1	DE MARRE, ANNE; et al, Synthesis and evaluation of macromolecular prodrugs of mitomycin C, Journal of Controlled Release, Special Issue 36 (1995) September, Nos. 112, Amsterdam, NL, pg. 87-97 ✓	<input type="checkbox"/>
	AO2	MATSUOKA, T., et al; Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer, Clinical and Experimental Metastasis, (1998 May) 16 (4) 381-8, XP -002154773 ✓	<input type="checkbox"/>
	AO3	NICHIFOR, MARIETA, et al; Chemical and enzymatic hydrolysis of dipeptide derivatives of 5-fluorouracil, Journal of Controlled Release 47 (1997) 271-281, XP 000689098 ✓	<input type="checkbox"/>
	A04	Abstract - 1998-231397 of Patent Application DE 19640970 ✓	<input type="checkbox"/>
	A05	PARK, JOHN E., et al; Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts, Journal of Biological Chemistry, (1999) 274 (51) 36505-12 ✓	<input type="checkbox"/>
	AO6	CALICETI, P. et al; Preparation and Properties of Monomethoxy Poly(Ethylene Glycol) Doxorubicin Conjugates Linked by an Amino Acid or a Peptide as Spacer, 2193 II Farmaco, (1993) 48 (7) 919-32 ✓	<input type="checkbox"/>
	AO7	STARCHER, BARRY et al; Inhibition of Neutrophil Elastase Suppresses the Development of Skin Tumors in Hairless Mice; Journal of Investigative Dermatology, (1996), Vol. 107:159-163 ✓	<input type="checkbox"/>
	AO8	HENDRIX, MARY J.C., et al; Expression of Type IV Collagenase Correlates with the Invasion of Human Lymphoblastoid Cells Lines and Pathogenesis in SCID Mice; Molecular and Cellular Probes (1992) 6. 59-65 ✓	<input type="checkbox"/>
	AO9	FIDLER, ISAIAH J.; Critical Factors in the Biology of Human Cancer Metastasis: Twenty Eight G.H.A. Clowes Memorial Award Lecture, Cancer Research 50, 6130-6138, October 1, 1990 ✓	<input type="checkbox"/>
	AO10	Editorials, The New England Journal of Medicine, Vol. 320, No. 8, pp 525-527 ✓	<input type="checkbox"/>
	AO11	SAIKI, IKUO; Antiadhesion Peptides in the Prevention of Tumour Metastasis, Disease Treatment Review, Clin. Immunother.1 (4) 1994 307-318 ✓	<input type="checkbox"/>
	AO12	D. THEODORESCU, et al; Dominance of Metastatically Competent Cells in Primary Murine Breast Neoplasms is Necessary for Distant Metastatic Spread, Int. J. Cancer; 47, 118-123, (1991) ✓	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--